These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35450742)

  • 21. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
    Drake MJ; MacDiarmid S; Chapple CR; Esen A; Athanasiou S; Cambronero Santos J; Mitcheson D; Herschorn S; Siddiqui E; Huang M; Stoelzel M
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28419650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
    Kim SC; Park M; Chae C; Yoon JH; Kwon T; Park S; Moon KH; Cheon SH; Park S
    Investig Clin Urol; 2021 May; 62(3):317-323. PubMed ID: 33834641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
    Katoh T; Igawa Y; Yamaguchi O; Kato D; Hamada T; Kuroishi K
    Low Urin Tract Symptoms; 2020 Jan; 12(1):68-80. PubMed ID: 31571403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
    Kinjo M; Sekiguchi Y; Yoshimura Y; Nutahara K
    Low Urin Tract Symptoms; 2018 May; 10(2):148-152. PubMed ID: 27911988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.
    Inoue M; Yokoyama T
    Acta Med Okayama; 2019 Oct; 73(5):387-392. PubMed ID: 31649364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
    Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial.
    Chen HX; Chang SH; Chen DY; Lan JL; Yeo KJ; Huang PH; Huang CM; Huang CP; Chou EC; Wu PC
    Low Urin Tract Symptoms; 2023 Jul; 15(4):139-147. PubMed ID: 37191196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).
    Abrams P; Kelleher C; Staskin D; Kay R; Martan A; Mincik I; Newgreen D; Ridder A; Paireddy A; van Maanen R
    World J Urol; 2017 May; 35(5):827-838. PubMed ID: 27514371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
    Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
    BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
    Soliman MG; El-Abd SA; Tawfik AM; Radwan MH; El-Abd AS
    World J Urol; 2021 Jun; 39(6):2049-2054. PubMed ID: 32869151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
    MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
    J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR; Siddiqui E
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study.
    Tang QL; Zhou S; Liu YQ; Wu J; Tao RZ
    Sci Rep; 2022 Nov; 12(1):18844. PubMed ID: 36344629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Mirabegron Add-on Therapy After Failure With Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Pilot Study.
    Mut SE; Selcuk F; İncirli SU; Delibas S
    Clin Neuropharmacol; 2024 Jul-Aug 01; 47(4):109-112. PubMed ID: 39008540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
    Wang CC; Kuo HC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):279-284. PubMed ID: 29843924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
    Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
    Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.